Phenomix Sciences Launches MyPhenome® Test Directly to Patients to Help Guide Weight Loss Treatment Based on Biology

Now available directly to patients, MyPhenome is the first and only precision obesity test that goes beyond GLP-1 treatment response to help guide treatment decisions across a broad range of obesity therapies and interventions.

MIB Agents' Community of Families Has Awarded $2.9M in Grants to Research Pediatric Bone Cancer

Cresset releases Flare V12 to cut synthesis and testing cycles with faster, more flexible FEP

Cresset has released Flare V12, a new version of its computer-aided drug design (CADD) solution for the discovery, design and optimization of small molecules. Flare V12 is focussed on improving access to Free Energy Perturbation (FEP) in drug discovery.

Novo Nordisk Brings Weight-Loss Treatment to a New Era as Wegovy® Pill Becomes UK's First Daily GLP-1 Obesity Tablet

Novo Nordisk's Wegovy® pill has become the first daily GLP-1 weight-loss tablet approved in the UK, offering adults with obesity and overweight a convenient alternative to weekly injections. The approval was based on the Phase 3 OASIS 4 trial, where patients achieved up to 16.6% average weight loss over 64 weeks. As obesity affects around 15 million people in the UK, the launch of this oral semaglutide treatment is expected to expand access to effective obesity care and strengthen the growing role of GLP-1 drugs in long-term weight management.

Mabion reactivates MabionCD20 through rare disease collaboration with Oddifact

Roche Secures Historic FDA Approval for First PTEN Companion Diagnostic in Prostate Cancer

Roche has received FDA approval for the VENTANA PTEN (SP218) RxDx Assay, the first companion diagnostic test designed to identify PTEN protein loss in patients with prostate adenocarcinoma. The breakthrough test helps clinicians determine which patients may benefit from AstraZeneca’s targeted therapy TRUQAP (capivasertib), advancing personalized cancer treatment. Supported by results from the CAPItello-281 clinical trial, the approval marks a significant step in precision oncology, offering new hope for patients with aggressive PTEN-deficient metastatic prostate cancer while reinforcing Roche’s leadership in companion diagnostics and personalized healthcare solutions.

Moderna and Oxford Secure $60 Million CEPI Funding to Advance Ebola Bundibugyo Vaccine Development During Congo Outbreak

CEPI has committed $60 million to accelerate Ebola Bundibugyo vaccine development with Moderna and the University of Oxford amid an ongoing outbreak in the Democratic Republic of Congo. The funding will support preclinical and early clinical development, along with manufacturing readiness for potential large-scale trials. Health agencies report 282 confirmed cases and 42 deaths, highlighting urgent containment needs. The initiative strengthens global vaccine R&D efforts focused on faster outbreak response and infectious disease preparedness.

FibroFind appoints new CEO to lead firm through next phase of growth

Alithea Genomics and Revvity Announce Distribution Agreement to Expand Access to MERCURIUSTM DRUG-seq Solutions

Alithea Genomics has announced a new agreement with Revvity Inc. to broaden access to MERCURIUS™ DRUG-seq and MERCURIUS™ Total DRUG-seq solutions through Revvity’s global commercial network.

Terrestrial Presents Data on Needle-Free Microarray Patch for Codelivery of Amylin Analog and GLP-1 Therapy Without Coformulation

Terrestrial Bio, Inc., a biotech company transforming the delivery of next-generation therapies, is presenting new preclinical data at the 2026 American Diabetes Association (ADA) Scientific Sessions in New Orleans.

Roche and Nurix Place a Multi-Billion-Dollar Bet on the Future of BTK Degradation

Nurix Therapeutics and Roche have announced a global collaboration to develop and commercialize bexobrutideg, an investigational BTK degrader designed to treat blood cancers, autoimmune disorders, and neurological diseases. Under the agreement, Nurix will receive a $700 million upfront payment and could earn up to $2.3 billion in additional milestone payments. Bexobrutideg is designed to eliminate the BTK protein rather than simply block its activity, potentially offering advantages over existing BTK inhibitors, including effectiveness against treatment-resistant disease. The partnership will support ongoing late-stage studies in chronic lymphocytic leukemia (CLL) while expanding development into multiple sclerosis (MS) and chronic spontaneous urticaria (CSU), aiming to unlock the therapy’s full potential across multiple disease areas.

Genesis AEC Highlights PharmaWater Pro® Modeling Capability for Early Stage Pharmaceutical Water System Design

Platform helps manufacturers evaluate sustainability, utilities, and lifecycle costs before committing to major infrastructure

Baxfendy’s FDA Approval Puts AstraZeneca on Track for a $5 Billion Cardiometabolic Opportunity

AstraZeneca has received FDA approval for Baxfendy, a first-in-class treatment for hypertension, marking a significant milestone in its cardiometabolic growth strategy. The company believes the drug could address a major unmet need among millions of patients with uncontrolled blood pressure and has the potential to generate up to $5 billion in peak annual revenue. AstraZeneca is also evaluating Baxfendy for chronic kidney disease, heart failure, and other related conditions. The approval strengthens the company's position in cardiovascular and metabolic care while supporting its long-term growth ambitions.

Acute Patients Embrace At-Home Monitoring, Emphasizing Device Comfort and Ease of Use as Driving Adoption

Vivalink’s latest survey highlights key drivers for patient compliance and retention in acute remote care programs

Moderna and Merck Report Five-Year Melanoma Data Showing Durable Benefit of Personalized Cancer Vaccine With KEYTRUDA

Moderna and Merck shared 5-year results from the KEYNOTE-942 study showing that their personalized mRNA cancer vaccine, intismeran autogene, combined with KEYTRUDA, significantly improves outcomes for high-risk melanoma patients. The treatment reduced the risk of cancer recurrence or death by 49% and distant metastasis or death by 59% compared to KEYTRUDA alone. It also showed encouraging overall survival trends and stronger immune responses driven by tumor-targeted T-cells. The therapy remained safe over long-term follow-up with mostly mild side effects, highlighting the potential of personalized cancer vaccines in future oncology care.

Sygnature Discovery collaborates with DaltonTx to advance AI-enabled drug discovery capabilities

Verista Announces Appointment of Michael Laferrera as Chief Executive Officer

Verista names seasoned healthcare and pharma services leader as CEO to drive strategic growth, innovation, and operational excellence.

PubHive Named Best Niche Literature Software Company 2026 – UK

PubHive wins 2026 UK award for AI-powered literature workflows supporting evidence, safety, regulatory, and life sciences teams.

TeleTracking Brings Real-Time Operational Intelligence Beyond the Hospital Walls with Operations IQ(R) Ambulatory

Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration

CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanized monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months